Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($2.52), $0.57 worse than the analyst estimate of ($1.95). Revenue for the quarter came in at $981 thousand versus the consensus estimate of $900 thousand.

“The Esperion Lipid Management Team continues to lay a strong and durable foundation for what we believe are highly anticipated approvals and launches of 2020 – bempedoic acid and the bempedoic acid / ezetimibe combination tablet. We’re especially proud to have completed enrollment in the landmark CLEAR cardiovascular outcomes trial with over 14,000 statin intolerant patients,” said Tim M. Mayleben, president and chief executive officer of Esperion. “Our excitement and confidence continue to grow as we near the potential approval and commercial launch of our cost-effective, convenient, once-daily, oral LDL-C lowering therapies for the millions of patients on maximally tolerated statins who need additional LDL-C lowering.”

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.